Public reactions to the revised Medicare drug pricing provisions in the Inflation Reduction Act

Since the Centers for Medicare & Medicaid Services (CMS) announced that it has revised its guidance for the Medicare Drug Price Negotiation Program, several organizations and individuals have voiced their opinions on the revisions. Mixed reactions  AARP, the largest non-profit, non-partisan organization advocating for older Americans, welcomed the revised guidance, marking the announcement as, “an important next step to bring down astronomically high drug prices.”  The Alliance for Aging Research also called on the positive side of the amendments to the guidance, highlighting CMS’ revised definition of the term ‘unmet medical need’ as well as planned undertaking of patient-focused listening...